An expert explains the basics of von Hippel-Lindau—related kidney cancer, and how a new drug for the disease is shaping the way patients are treated. Patients with von Hippel-Lindau (VHL) disease are ...

When Joseph Heisler was diagnosed with von Hippel-Lindau disease 30 years ago, there was hardly any information on the condition. Fast forward three decades, there is an FDA-approved drug and a ...

JACKSONVILLE, Fla. — Von-Hippel-Lindau disease, otherwise known as VHL, is a genetic mutation that causes cancer to form in the body. This process tends to happen while in utero. According to ...

Belzutifan makes von Hippel-Lindau disease more manageable, according to an expert. Approval of belzutifan for treatment of kidney cancers and other neoplasms associated with von Hippel-Lindau (VHL) ...

Merck & Co., Inc. MRK announced that the FDA accepted the new drug application (“NDA”) for its novel investigational candidate, belzutifan. The company is seeking approval of belzutifan, a HIF-2α ...

The approval was based on data from an open-label phase 2 study which evaluated the efficacy and safety of Welireg in patients with von Hippel-Lindau-associated renal cell carcinoma and other ...

Researchers have mapped all the possible outcomes of changes to a tumor-suppressing gene called VHL, the first step in a huge research endeavor to unpick the outcomes of tens of thousands of genetic ...

DALLAS--(BUSINESS WIRE)--Peloton Therapeutics, Inc., announced today dosing of the first patient in a Phase 2 trial evaluating the efficacy and safety of lead investigational oncology agent, PT2977, ...

JACKSONVILLE, Fla. — At the age of twenty-three, I'm working the job of my dreams looking to start my own charity foundation. Then, out of nowhere, I'm blindsided with the news that I have a rare ...

ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results Patients diagnosed with hereditary RC are more prone to ...